Developmental and Epileptic Encephalopathies (DEEs) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
Developmental
and Epileptic Encephalopathies (DEEs) Emerging Therapy and TPP Insights
Thelansis’s “Developmental
and Epileptic Encephalopathies (DEEs) Emerging Therapy, with Unmet Needs and
TPP Insights Report – 2026″ provides a comprehensive analysis of the
emerging competitive landscape, unmet needs, target product profiles (TPPs),
trial designs, and KOL insights on key emerging therapies and key drug
development opportunities in the indication.
Developmental
and Epileptic Encephalopathies (DEEs) Overview
Developmental
and epileptic encephalopathies (DEEs) are a heterogeneous group of severe,
pediatric-onset neurodevelopmental syndromes characterized by drug-resistant
epilepsy, developmental stagnation or regression, and cognitive deficits.
Unlike classic epilepsies, DEEs damage neurodevelopment through both the
underlying genetic or structural etiology and the continuous, disruptive
electrographic activity itself. Syndromic archetypes like Dravet,
Lennox-Gastaut, and SCN2A/8A mutations are routinely confirmed via advanced
multigene panels, which have replaced broad diagnostic guesswork. While
standard broad-spectrum antiseizure medications (such as fenfluramine and
cannabidiol) provide baseline symptom mitigation, the field has aggressively
moved into an era of genotype-specific precision pharmacology. The current
landscape is anchored by targeted central nervous system therapeutics designed
to address specific ion channel variants. A landmark shift involves
relutrigine, a selective inhibitor of persistent sodium currents under FDA
Priority Review with a target action date of December 27, 2026, for SCN2A and
SCN8A DEEs, complemented by its broad-DEE Phase 3 EMERALD trial. Concurrently,
the antisense oligonucleotide (ASO) pipeline has achieved dramatic success, led
by zorevunersen (STK-001) for Dravet syndrome and elsunersen, which recently
demonstrated a 77% placebo-adjusted monthly seizure reduction in early-onset
SCN2A-DEE. These targeted molecular frameworks offer the first true
disease-modifying prospects to stabilize both seizure activity and underlying
cognitive trajectories.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and
enriched by insights from interviews with leading KOLs
*Survey is
customized based on client requirements
Deliverables
format:
- PowerPoint presentation
- MS Excel
Key business
questions answered:
- Detailed emerging competitive
landscape
- Pipeline
analysis
- Target patients
for emerging therapies
- Key companies
- Key mechanism of
actions
- Launch date
estimates, etc.
- Clinical trial landscape analysis
- Target patient
segments
- Trial endpoints
- Trial design
- Recruitment
criteria, etc.
- Unmet Needs and Opportunities
- Performance of
key current therapies
- Top areas of
unmet needs
- Opportunity
sizing for key unmet needs
- Target Product Profiles
- Attributes and
levels
- Physician
likelihood of prescribing
- Expected patient
shares
- KOL insights on key emerging
therapies
- Level of
awareness
- Expected use /
line of therapy
- Extent to fulfil
key unmet needs
- KOL quotes
Comments
Post a Comment